Skip to main content
Formycon AG logo

Formycon AG — Investor Relations & Filings

Ticker · FYB ISIN · DE000A1EWVY8 LEI · 39120005TZ76GQOY8Z19 F Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2013-04-08 Capital/Financing Update
Country DE Germany
Listing F FYB

About Formycon AG

https://www.formycon.com/en/

Formycon AG is an independent, globally operating biopharmaceutical company specializing in the development of high-quality biosimilars. As a pure-play biosimilar developer, the company focuses on creating follow-on products for complex biopharmaceutical medicines after their patent protection has expired. The core mission is to enhance patient access to safe, effective, and affordable biologic therapies. Formycon's development activities are concentrated in therapeutic areas with high medical need, including ophthalmology and immunology. The company manages the entire development process, from analytics and process development to clinical trials and regulatory approval submissions for its biosimilar candidates.

Recent filings

Filing Released Lang Actions
Formycon AG fuhrt weitere erfolgreiche Kapitalerhohung aus genehmigtem Kapital durch
Capital/Financing Update Classification · 98% confidence The document is a corporate news release dated April 8, 2013, announcing that Formycon AG successfully executed a capital increase ('Kapitalerhöhung') by placing new shares with institutional investors. The key phrases are 'Kapitalerhöhung', 'Barkapitalerhöhung', and the resulting increase in share capital. This directly relates to changes in the company's financing or capital structure. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document is a direct announcement of the event, not a proxy statement or a general regulatory filing fallback.
2013-04-08 German
Formycon AG: Kapitalerhohung bei strategischen Investoren vollstandig platziert
Share Issue/Capital Change Classification · 98% confidence The document is a corporate news release dated February 22, 2013, announcing that Formycon AG has successfully placed a capital increase ('Kapitalerhöhung') with strategic investors. Key phrases include 'Kapitalerhöhung bei strategischen Investoren vollständig platziert', the issuance of new shares, the gross inflow of funds, and the increase in the share capital ('Grundkapital'). This directly relates to fundraising, financing activities, and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document is a direct announcement of the event, not a report about it, ruling out RPA or RNS as the primary classification.
2013-02-22 German
Formycon AG beschliet Kapitalerhohung mit Bezugsrecht
Share Issue/Capital Change Classification · 98% confidence The document is a corporate news release dated January 11, 2013, announcing that the Management Board of Formycon AG has resolved to increase the share capital through the issuance of new shares via a rights offering ('Kapitalerhöhung mit Bezugsrecht'). This action directly relates to changes in the company's capital structure and fundraising activities. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). Although it involves shares, it is a planned capital increase announcement, not a report of a transaction in own shares (POS) or a general share issue (SHA), but specifically a financing event.
2013-01-11 German
Formycon AG beginnt mit der Entwicklung des ersten Biosimilars
Regulatory Filings Classification · 100% confidence The document is a news release dated January 8, 2013, from Formycon AG, announcing the start of development for its first proprietary biosimilar product candidate in Q4 2012. It details the market potential, regulatory approach, and internal capabilities. This type of announcement, focusing on a specific business development (product pipeline progression) rather than routine financial results (ER/IR) or mandatory regulatory filings (10-K/AR), fits best under the general category of corporate news or updates that don't align with the more specific codes like DIV, DIRS, or CAP. Since it is a general corporate announcement distributed via DGAP, and it doesn't fit the definitions for ER, IR, LTR, or CAP, the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general regulatory announcement/news category for items not explicitly defined elsewhere.
2013-01-08 German
Nanohale AG (Formycon) beruft Dr. Carsten Brockmeyer, Eigentumer und Geschaftsfuhrer der Brockmeyer Biopharma GmbH, in den wissenschaftlichen Beirat
Board/Management Information Classification · 100% confidence The document is a short corporate news release dated August 16, 2012, announcing the appointment of Dr. Carsten Brockmeyer to the scientific advisory board of Nanohale AG. The content focuses entirely on personnel changes (a new board member) and the strategic implications for the company's biosimilars business. This directly matches the definition for Board/Management Information (MANG). It is not an earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), as it pertains to a specific management/board event.
2012-08-16 German
Nanohale AG schliet Kapitalerhohung erfolgreich ab
Share Issue/Capital Change Classification · 99% confidence The document is a corporate news release dated July 13, 2012, titled 'Nanohale AG schließt Kapitalerhöhung erfolgreich ab' (Nanohale AG successfully completes capital increase). The content explicitly details the successful placement of new shares, the resulting gross inflow of funds (1,518,012.00 Euro), and the resulting increase in the company's share capital. This directly relates to fundraising, financing activities, and capital structure changes. This aligns perfectly with the definition for Capital/Financing Update (CAP). The document is short and appears to be the primary announcement, not a notice about a separate report.
2012-07-13 German

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.